These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 24906971)

  • 1. Measuring progress in neglected disease drug development.
    Cohen JP; Sturgeon G; Cohen A
    Clin Ther; 2014 Jul; 36(7):1037-42. PubMed ID: 24906971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of and access to products for neglected diseases.
    Cohen J; Dibner MS; Wilson A
    PLoS One; 2010 May; 5(5):e10610. PubMed ID: 20485552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of follow-on drugs and indications on the WHO Essential Drug List.
    Cohen J; Cabanilla L; Sosnov J
    J Clin Pharm Ther; 2006 Dec; 31(6):585-92. PubMed ID: 17176363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment.
    Pedrique B; Strub-Wourgaft N; Some C; Olliaro P; Trouiller P; Ford N; Pécoul B; Bradol JH
    Lancet Glob Health; 2013 Dec; 1(6):e371-9. PubMed ID: 25104602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of Product Development Partnerships in research and development for neglected diseases.
    Moran M; Guzman J; Ropars AL; Illmer A
    Int Health; 2010 Jun; 2(2):114-22. PubMed ID: 24037470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the landscape of US orphan product approvals.
    Miller KL; Lanthier M
    Orphanet J Rare Dis; 2018 Oct; 13(1):183. PubMed ID: 30348193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drugs in India over the past 15 years: analysis of trends.
    Ghosh A; Hazra A; Mandal SC
    Natl Med J India; 2004; 17(1):10-6. PubMed ID: 15115225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of and trends in the late-stage biopharmaceutical pipeline.
    Nagle PC; Nicita CA; Gerdes LA; Schmeichel CJ
    Am J Manag Care; 2008 Apr; 14(4):226-9. PubMed ID: 18402515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent drug approvals from the US FDA and EMEA: what the future holds.
    Pevarello P
    Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
    Shimazawa R; Ikeda M
    Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.
    Lanthier M; Miller KL; Nardinelli C; Woodcock J
    Health Aff (Millwood); 2013 Aug; 32(8):1433-9. PubMed ID: 23918488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economics of new oncology drug development.
    DiMasi JA; Grabowski HG
    J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [International Partnership for Therapeutic Drug Development of NTDs by DNDi].
    Yamada H; Hirabayashi F; Brünger C
    Yakugaku Zasshi; 2016; 136(2):213-22. PubMed ID: 26831796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.
    Sridhara R; Johnson JR; Justice R; Keegan P; Chakravarty A; Pazdur R
    J Natl Cancer Inst; 2010 Feb; 102(4):230-43. PubMed ID: 20118413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
    Thorat C; Xu K; Freeman SN; Bonnel RA; Joseph F; Phillips MI; Imoisili MA
    Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.